• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

近期新药获批情况，第二部分：正在儿童中进行积极临床研究的药物。

Recent new drug approvals, part 2: drugs undergoing active clinical studies in children.

作者信息

Chhim Rebecca F, Shelton Chasity M, Christensen Michael L

机构信息

Departments of Clinical Pharmacy ; Le Bonheur Children's Hospital, Memphis, Tennessee.

出版信息

J Pediatr Pharmacol Ther. 2013 Jan;18(1):14-38. doi: 10.5863/1551-6776-18.1.14.

DOI:10.5863/1551-6776-18.1.14
PMID:23616733
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3626063/
Abstract

The objective of this 2-part review is to provide information about drugs that have been recently approved by the US Food and Drug Administration. Part 1 reviewed recently approved drugs with pediatric indications. Part 2 reviews drugs recently approved only in adults and have published or ongoing studies in children.

摘要

这篇分两部分的综述旨在提供有关美国食品药品监督管理局最近批准的药物的信息。第一部分回顾了最近批准的有儿科适应症的药物。第二部分回顾了最近仅在成人中批准且已发表或正在进行儿童研究的药物。

相似文献

1
Recent new drug approvals, part 2: drugs undergoing active clinical studies in children.近期新药获批情况，第二部分：正在儿童中进行积极临床研究的药物。
J Pediatr Pharmacol Ther. 2013 Jan;18(1):14-38. doi: 10.5863/1551-6776-18.1.14.
2
Recent new drug approvals. Part 1: drugs with pediatric indications.近期新药获批情况。第一部分：有儿科适应症的药物。
J Pediatr Pharmacol Ther. 2012 Oct;17(4):329-39. doi: 10.5863/1551-6776-17.4.329.
3
Innovating by developing new uses of already-approved drugs: trends in the marketing approval of supplemental indications.通过开发已批准药物的新用途进行创新：补充适应症营销批准的趋势。
Clin Ther. 2013 Jun;35(6):808-18. doi: 10.1016/j.clinthera.2013.04.004. Epub 2013 May 28.
4
Characteristics of efficacy evidence supporting approval of supplemental indications for prescription drugs in United States, 2005-14: systematic review.2005 - 2014年美国支持处方药补充适应症获批的疗效证据特征：系统评价
BMJ. 2015 Sep 23;351:h4679. doi: 10.1136/bmj.h4679.
5
Completion Rate and Reporting of Mandatory Pediatric Postmarketing Studies Under the US Pediatric Research Equity Act.美国儿科研究公平法案下强制性儿科上市后研究的完成率和报告情况。
JAMA Pediatr. 2019 Jan 1;173(1):68-74. doi: 10.1001/jamapediatrics.2018.3416.
6
U.S. Food and Drug Administration anticancer drug approval trends from 2016 to 2018 for lung, colorectal, breast, and prostate cancer.2016 年至 2018 年美国食品和药物管理局批准的肺癌、结直肠癌、乳腺癌和前列腺癌抗癌药物趋势。
Int J Technol Assess Health Care. 2020;36(1):20-28. doi: 10.1017/S0266462319000813. Epub 2019 Nov 28.
7
Postapproval studies of drugs initially approved by the FDA on the basis of limited evidence: systematic review.对最初基于有限证据经美国食品药品监督管理局批准的药物进行的批准后研究：系统评价
BMJ. 2017 May 3;357:j1680. doi: 10.1136/bmj.j1680.
8
Pediatric Drug Development in Japan: A Comparison of the Current Situation and Characteristics Between Japan and Europe.日本儿科药物开发：日本与欧洲的现状和特点比较。
Ther Innov Regul Sci. 2020 Sep;54(5):1152-1158. doi: 10.1007/s43441-020-00136-0. Epub 2020 Mar 4.
9
FDA Approval and Regulation of Pharmaceuticals, 1983-2018.FDA 对药品的批准与监管，1983-2018 年。
JAMA. 2020 Jan 14;323(2):164-176. doi: 10.1001/jama.2019.20288.
10
Status of drug approval processes and regulation of medications for children.
Curr Opin Pediatr. 1995 Apr;7(2):195-8. doi: 10.1097/00008480-199504000-00014.

引用本文的文献

1
Dual pH- and Thermo-Sensitive Poly(N-isopropylacrylamide-co-allylamine) Nanogels for Curcumin Delivery: Swelling-Deswelling Behavior and Phase Transition Mechanism.用于姜黄素递送的双pH和温度敏感型聚（N-异丙基丙烯酰胺-共-烯丙胺）纳米凝胶：溶胀-消溶胀行为及相变机制
Gels. 2023 Jul 1;9(7):536. doi: 10.3390/gels9070536.
2
Diagnosis and management of cerebral venous sinus thrombosis in children: a single-center retrospective analysis.儿童脑静脉窦血栓形成的诊断与治疗：单中心回顾性分析。
Childs Nerv Syst. 2021 Jan;37(1):153-160. doi: 10.1007/s00381-020-04958-z. Epub 2020 Nov 6.
3
Efficacy and safety of combined oral iron chelation therapy with deferasirox and deferiprone in a patient with beta-thalassemia major and persistent iron overload.地拉罗司与去铁酮联合口服铁螯合疗法治疗重型β地中海贫血伴持续性铁过载患者的疗效和安全性
Blood Res. 2014 Mar;49(1):72-3. doi: 10.5045/br.2014.49.1.72. Epub 2014 Mar 24.

本文引用的文献

1
Safety and efficacy of ezogabine (retigabine) in adults with refractory partial-onset seizures: Interim results from two ongoing open-label studies.依佐加滨（瑞替加滨）治疗成人难治性部分发作性癫痫的安全性和有效性：两项正在进行的开放性研究的中期结果。
Epilepsy Res. 2012 Nov;102(1-2):117-21. doi: 10.1016/j.eplepsyres.2012.05.007. Epub 2012 Jul 5.
2
Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study.本妥昔单抗维迪昔（SGN-35）治疗复发或难治性系统性间变大细胞淋巴瘤患者的Ⅱ期研究结果。
J Clin Oncol. 2012 Jun 20;30(18):2190-6. doi: 10.1200/JCO.2011.38.0402. Epub 2012 May 21.
3
Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma.一项评估 Brentuximab vedotin 治疗复发或难治性霍奇金淋巴瘤患者的关键性 II 期研究结果。
J Clin Oncol. 2012 Jun 20;30(18):2183-9. doi: 10.1200/JCO.2011.38.0410. Epub 2012 Mar 26.
4
Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib.维莫非尼治疗 BRAF V600 突变型晚期黑色素瘤的生存情况。
N Engl J Med. 2012 Feb 23;366(8):707-14. doi: 10.1056/NEJMoa1112302.
5
Multisite analytic performance studies of a real-time polymerase chain reaction assay for the detection of BRAF V600E mutations in formalin-fixed, paraffin-embedded tissue specimens of malignant melanoma.多中心实时聚合酶链反应检测法分析BRAF V600E 基因突变在福尔马林固定石蜡包埋的恶性黑色素瘤组织标本中的应用
Arch Pathol Lab Med. 2012 Nov;136(11):1385-91. doi: 10.5858/arpa.2011-0505-OA. Epub 2012 Feb 14.
6
Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial. fidaxomicin 与万古霉素治疗欧洲、加拿大和美国艰难梭菌感染：一项双盲、非劣效、随机对照试验。
Lancet Infect Dis. 2012 Apr;12(4):281-9. doi: 10.1016/S1473-3099(11)70374-7. Epub 2012 Feb 8.
7
The mechanism of action of retigabine (ezogabine), a first-in-class K+ channel opener for the treatment of epilepsy.瑞替加滨（依佐加滨）作用机制，一种用于癫痫治疗的首个钾通道开放剂。
Epilepsia. 2012 Mar;53(3):412-24. doi: 10.1111/j.1528-1167.2011.03365.x. Epub 2012 Jan 5.
8
Crizotinib: a novel and first-in-class multitargeted tyrosine kinase inhibitor for the treatment of anaplastic lymphoma kinase rearranged non-small cell lung cancer and beyond.克唑替尼：一种新型的、同类首创的多靶点酪氨酸激酶抑制剂，用于治疗间变性淋巴瘤激酶重排的非小细胞肺癌及其他疾病。
Drug Des Devel Ther. 2011;5:471-85. doi: 10.2147/DDDT.S19045. Epub 2011 Nov 23.
9
Vandetanib for the treatment of thyroid cancer.凡德他尼用于甲状腺癌的治疗。
Clin Pharmacol Ther. 2012 Jan;91(1):71-80. doi: 10.1038/clpt.2011.272. Epub 2011 Dec 7.
10
Randomized placebo-controlled trial of the bradykinin B₂ receptor antagonist icatibant for the treatment of acute attacks of hereditary angioedema: the FAST-3 trial.依卡替班特治疗遗传性血管性水肿急性发作的随机安慰剂对照试验：FAST-3 试验。
Ann Allergy Asthma Immunol. 2011 Dec;107(6):529-37. doi: 10.1016/j.anai.2011.08.015. Epub 2011 Oct 5.